Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?

•Bevacizumab induced HTN in gynecologic cancers has a resolution rate of 82% with a median of 87 days.•We found no specific risk factors for development of bevacizumab induced HTN in gynecologic cancers.•Development of bevacizumab induced hypertension does not correlate with improved PFS in our cohort.

Hypertension (HTN) induced by bevacizumab is a side effect that is often thought to resolve after treatment. However, there are currently no reports on rates of resolution. We assess the incidence and timing of the resolution of bevacizumab induced HTN.We evaluated all patients treated with bevacizumab for gynecologic malignancies at a single institution from 2012 through 2014. HTN was retrospectively diagnosed and staged by CTCAE v4.0 criteria. Resolution of HTN was defined as ≥ 2 values return to baseline blood pressure and/or discontinuation/decrease of blood pressure medications.We identified 104 patients; 35 were excluded due to receiving bevacizumab at time of analysis. Grade 2 or higher induced HTN was identified in 34/69 (49.3%) patients, of which 26/69 (37.7%) had grade 2 HTN and 8/69 (11.6%) had grade 3/4 HTN. Onset of HTN occurred at a median of 67 (14–791) days. Resolution of HTN occurred in 28/34 (82.4%) patients with a median time to resolution of 87 (3–236) days. BMI, history of HTN, blood pressure medications, prior bevacizumab treatment, number of bevacizumab cycles, CA-125 and albumin at initiation of treatment were not independent risk factors associated with developing HTN in multivariate analysis. Median PFS for those with HTN was 12.5 (1.9–45.8) months vs 11.0 (2.1–44.7) for those without (p = 0.17).Hypertension induced by bevacizumab resolved in 82% of patients in a median of 87 days. There were no identifiable risk factors associated with induced HTN and HTN was not a biomarker for improved prognosis in our cohort.